Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study.
Arterial hypertension
Arterial stiffness
Bisoprolol
Moxonidine
Telomerase activity
Vascular aging
Journal
Cardiovascular drugs and therapy
ISSN: 1573-7241
Titre abrégé: Cardiovasc Drugs Ther
Pays: United States
ID NLM: 8712220
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
accepted:
29
07
2021
pubmed:
16
9
2021
medline:
16
11
2022
entrez:
15
9
2021
Statut:
ppublish
Résumé
To compare the effect of 12 months of treatment with moxonidine or bisoprolol on telomerase activity (TA) and parameters characterizing the arterial wall state in postmenopausal women with arterial hypertension (AH) and osteopenia. An open-label randomized study with 114 postmenopausal women with hypertension and osteopenia; pulse wave velocity (PWV), intima-media thickness (IMT), and TA were analyzed initially and after 12 months of therapy with moxonidine (n = 57) or bisoprolol (n = 57). Both medications effectively lowered blood pressure (BP) in both groups. After 12 months, the moxonidine group showed a significant increase in TA by 45.5% (from 0.87 to 1.15; p < 0.001), in contrast to the bisoprolol group, where TA decreased by 14.1% (from 0.89 to 0.74; p = 0.001). Within 12 months, in the moxonidine group, PWV decreased by 1.9% (from 10.35 ± 2.56 to 10.05 ± 2.29 m/s; p = 0.039), and in the bisoprolol group it increased by 5.8% (from 10.36 ± 2.47 to 11.26 ± 2.60 m/s; p < 0.001). In the moxonidine group, IMT increased by 3.5% on the right and 1.4% on the left, in the bisoprolol group - by 5.7% on the right and 4.2% on the left. A 12-month treatment with moxonidine but not with bisoprolol in postmenopausal women with AH and osteoporosis was associated with a decrease of arterial stiffness seen as statistically significantly reduced PVW and with increased TA.
Identifiants
pubmed: 34524565
doi: 10.1007/s10557-021-07235-6
pii: 10.1007/s10557-021-07235-6
doi:
Substances chimiques
Antihypertensive Agents
0
Bisoprolol
Y41JS2NL6U
moxonidine
CC6X0L40GW
Telomerase
EC 2.7.7.49
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1147-1155Informations de copyright
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.
Références
McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. Osteoporosis and cardiovascular disease. Endocrine. 2004;23:1–10.
doi: 10.1385/ENDO:23:1:01
pubmed: 15034190
Browner WS, Seeley DG, Cummings SR, Vogt TM, Group FTSOOFR. Non-trauma mortality in elderly women with low bone mineral density. Lancet Elsevier. 1991;338:355–8.
doi: 10.1016/0140-6736(91)90489-C
Browner WS, Pressman AR, Nevitt MC, Cauley JA, Cummings SR. Association between low bone density and stroke in elderly women. The study of osteoporotic fractures. Stroke. Am Heart Assoc. 1993;24:940–6.
Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Lancet. Elsevier. 1999;354:971–5.
doi: 10.1016/S0140-6736(99)01437-3
Wiklund P, Nordström A, Jansson J-H, Weinehall L, Nordström P. Low bone mineral density is associated with increased risk for myocardial infarction in men and women. Osteoporos Int. 2012;23:963–70.
doi: 10.1007/s00198-011-1631-0
pubmed: 21505909
Farhat GN, Cauley JA. The link between osteoporosis and cardiovascular disease. Clin cases miner bone Metab. CIC Edizioni Int. 2008;5:19–34.
Strazhesko ID, Akasheva DU, Dudinskaya EN, Tkacheva ON. Vascular ageing: main features and mechanisms. Cardiovasc Ther Prev. 2012;11(4).
Nilsson PM, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G, et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31:1517–26.
Fragkiadaki P, et al. Telomere length and telomerase activity in osteoporosis and osteoarthritis (review). Exp Ther Med. 2020;19:1626–32.
pubmed: 32104213
Blackburn EH. Telomere states and cell fates. Nature. 2000;408:53–6.
doi: 10.1038/35040500
pubmed: 11081503
Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12:1133–8.
doi: 10.1038/nm1006-1133
pubmed: 17024208
Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001; 12:602 LP–605.
Krespi P, et al. Moxonidine effect on microalbuminuria, trombomodulin, and plasminogen activator ingibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther. 1998;12:463–7.
Waters J, et al. Use of moxonidine as unitial therapy and in combination in the treatment of essential hypertension: results of the TOPIC (trial of Physiotens in combination) study. J Clin Basic Cardiol. 1999;2:219–24.
Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004;18:669–75.
doi: 10.1038/sj.jhh.1001676
pubmed: 15269705
Podzolkov V, et al. Moxonidine in combined therapy of metabolic syndrome. Arte Hypertens. 2008;https://doi.org/10.18705/1607-419X-2007-13-4-246-249.
Rapelli A. Hypertension and obesity in menopause. J Hypertens. 2002;20:S26–8.
Eruslanova K, Dudinskaya E, Bazaeva E, Tkacheva O. The positive effect of moxonidine on telomerase activity. J Hypertens. Ovid Technologies (Wolters Kluwer Health); 2021;39:e95. Available from: https://journals.lww.com/10.1097/01.hjh.0000745348.75502.24
Channaraya V, Marya RK, Somasundaram M, Mitra D, Tibrewala KD. Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study. BMJ Open. 2012;2(3):e000683.
Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care. 2005;20:187–91.
doi: 10.1016/j.jcrc.2005.04.005
pubmed: 16139163
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021–104.
doi: 10.1093/eurheartj/ehy339
pubmed: 30165516
Dudinskaya E, Tkacheva O, Bazaeva E. Etc. new opportunities of using moxonidin for control of blood pressure in patients with osteoporosis. Kardiologia. 2018;S7:36–45.
doi: 10.18087/cardio.2508
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5.
doi: 10.1126/science.7605428
pubmed: 7605428
Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30:445–8.
Nilsson P, et al. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009;54:3–10.
doi: 10.1161/HYPERTENSIONAHA.109.129114
pubmed: 19487587
Jockel-Schneider Y, Harks I, Haubitz I, Fickl S, Eigenthaler M, Schlagenhauf U, et al. Arterial stiffness and pulse wave reflection are increased in patients suffering from severe periodontitis. PLoS One. Public Libr Sci; 2014;9:e103449.
Engelen L, Ferreira I, Stehouwer CD, Boutouyrie P, Laurent S. Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. Eur Heart J. 2013 ;34:2368–80. https://academic.oup.com/eurheartj/article/34/30/2368/486500
Jarauta E, Mateo-Gallego R, Bea A, Burillo E, Calmarza P, Civeira F. Carotid Intima-Media Thickness in Subjects With No Cardiovascular Risk Factors. Rev Española Cardiol (English Ed [Internet]. Elsevier BV; 2010 [cited 2021 Apr 30];63:97–102. http://www.revespcardiol.org/en-carotid-intima-media-thickness-in-subjects-articulo-13146858
Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest Am Soc Clin Invest. 2017;127:1–4.
doi: 10.1172/JCI92035
Webb DR, Khunti K, Silverman R, Gray LJ, Srinivasan B, Lacy PS, et al. Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. Diabetologia. 2010;53:1190–8.
Friedman J, Ishizuka T, Liu S, Farrell C, Koletsky R, Bedol D, et al. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Blood Press Suppl. 1998;3:32–9.
pubmed: 10321453
Ernsberger P, Friedman J, Koletsky R. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens Suppl.1997;15:S9–23. Available from: /pmc/articles/PMC1351308/.
Ebinç H, Ozkurt ZN, Ebinç FA, Ucardag D, Caglayan O, Yilmaz M. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women. J Int Med Res [Internet]. Cambridge Medical Publications; 2008 [cited 2021 May 4];36:80–7. Available from: https://pubmed.ncbi.nlm.nih.gov/18230271/
Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes, Obes Metab. 2006;8:456–65. Available from: https://pubmed.ncbi.nlm.nih.gov/16776753/
Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol. 2013;10:274–83.
Aix E, Gallinat A, Flores I. Telomeres and telomerase in heart regeneration. Differentiation. 2018;100:26–30.
doi: 10.1016/j.diff.2018.01.003
pubmed: 29453108
Serrano AL, Andrés V. Telomeres and cardiovascular disease. Circ Res Am Heart Association. 2004;94:575–84.
Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis. Circ Res. Am Heart Association. 2006;99:156–64.
Xin F, Lining W, Yao L. Change of telomere length in angiotensin ii-induced human glomerular mesangial cell senescence and the protective role of losartan. Mol Med Rep. 2011;4:255–60.
Le Brigand L, Virsolvy A, Peyrollier K, Manechez D, Godfroid JJ, Guardiola-Lemaître B, et al. Stimulation of insulin release from the MIN6 cell line by a new imidazoline compound, S-21663: evidence for the existence of a novel imidazoline site in β cells. Br J Pharmacol. 1997;122:786–91. https://doi.org/10.1038/sj.bjp.0701449.
Efanov AM, Zaitsev SV, Mest HJ, Raap A, Appelskog IB, Larsson O, et al. The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity. Diabetes. 2001;50:797–802. Available from: https://pubmed.ncbi.nlm.nih.gov/11289044/
Olsen HL, Nørby PL, Høy M, Spee P, Thams P, Capito K, et al. Imidazoline NNC77–0074 stimulates Ca2+−evoked exocytosis in INS-1E cells by a phospholipase A2-dependent mechanism. Biochem Biophys Res Commun. 2003;303:1148–51. Available from: https://pubmed.ncbi.nlm.nih.gov/12684056/
Prichard BNC, Graham BR. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors. Implications for the treatment of the elderly. Drugs Aging. 2000;17:133–59. Available from: https://pubmed.ncbi.nlm.nih.gov/10984201/
Tesfai J, Crane, L, Mouysset GB. Novel I1-Imidazoline agonist S43126 augment insulin secretion in Min6 cells. J Diabetes Metab. 2012;3:183.
Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366:662–4. https://pubmed.ncbi.nlm.nih.gov/16112303/
Coluzzi E, Leone S, Sgura A. Oxidative stress induces telomere dysfunction and senescence by replication fork arrest. Cells. 2019;8:19. https://doi.org/10.3390/cells8010019.
Mangge H, Herrmann M, Almer G, Zelzer S, Moeller R, Horejsi R, et al. Telomere shortening associates with elevated insulin and nuchal fat accumulation. Sci Rep. 2020;10:1–9.
De Zegher F, Díaz M, Ibáñez L. Association between long telomere length and insulin sensitization in adolescent girls with hyperinsulinemic androgen excess. JAMA Pediatr. 2015;169:787–8. https://jamanetwork.com/
Jose SS, Bendickova K, Kepak T, Krenova Z, Fric J. Chronic inflammation in immune aging: Role of pattern recognition receptor crosstalk with the telomere complex?. Front Immunol. 2017;8:1078.